Drugs / ALVAC-RG Rabies Glycoprotein
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000813 | ? → Jun 1995 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000847 | ? → May 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001072 | ? → Jan 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001076 | ? → Dec 1997 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-RG Rabies Glycoprotein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001076 ↗ |
| Known as | vCP65 | “ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00001072 ↗3“ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00001076 ↗ “ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00000847 ↗ “ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00000813 ↗ |
| Modality | Vaccine | “a recombinant canarypox expressing the rabies glycoprotein (ALVAC rabies glycoprotein) as a control” NCT00000813 ↗ |
| Route | Intramuscular | “intramuscular injections of ALVAC gp160 MN at a dose of 1 million TCID50 or ALVAC rabies glycoprotein as a control” NCT00000813 ↗ |